Lorem lacus proin sapien quis pretium quis praesent vel sit a blandit massa ornare molestie hendrerit non porttitor blandit dictum ornare laoreet non dolor massa congue adipiscing gravida sagittis libero amet congue vel volutpat ut eros orci venenatis nunc congue lacus accumsan nec accumsan sit proin quisque dictum dictum eleifend
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today FDA approval of an additional claim for the cobas® Zika test for use on the cobas® 6800/8800 Systems. The newly approved claim allows for the streamlined screening of multiple individual blood or plasma donations that have been pooled together.
Roche announced today that the US Food and Drug Administration (FDA) has provided 510(k) clearance for cobas® CT/NG for use on the cobas® 6800/8800 Systems for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in both symptomatic and asymptomatic individuals.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA clearance for the cobas® Factor II and Factor V Test for use on the cobas® 4800 system. The test enables laboratories to simultaneously assess Factor II and Factor V gene mutations from a single patient sample, which can reduce hands-on time when testing patients for inherited thrombophilia.
Please contact your Roche representative if you have any questions about your MagNA Pure System.
Download agendas, request meeting or reserve in-booth presentation spot
To download, please provide your contact information.
You are now leaving molecular.roche.com
The site you are about to visit is maintained by a third party. Roche Molecular Systems has no control over the content of third-party sites, nor does it endorse or accept attribution for the claims, comments and opinions expressed on them.
Click "Continue" to proceed or "Return" to return to molecular.roche.com.